Index
191
Gold (I), catalyzed cycloaddition, 94
Gold nanoparticles, nanoclusters, 145, 149
Gram stain
Gram-negative, 2, 3
Gram-positive, 2
GSK690693, dual inhibitor, 173
GT-055, hybrid, 33
GT-1, hybrid, 33
Gyrase A, 62
H
Halicin, 12
Helicobacter pylori, 37, 44, 83, 97
HHQ, quinolone signal molecule, 171
High throughput screening, 58
Holliday junctions, 178
Holmes, Sherlock, 87
Host, defence proteins, disarming, 179
HT 61, antibiofilm activity, 164
Humimycins A and B, 165
Hybrids, antibacterial, Chapter 3, 52
Hydrogen peroxide, 41, 129
Hydroxyl radicals, 38
I
Imipenem, 31
INF55, 74
INF55-(Ac)en-MB 2, hybrid, 38
In silico-based design, 31, 57, 60, 89, 90, 96,
180
Iron (III), 12, 85
Irresistin-16, dual action, 61
Isothiazoloquinolone derivative, 60
K
Kanglemycin, 82
Klebsiella pneumonia, introduction, 3, 9, 15
L
LasR protein, 172
LED209, histidine sensor kinase, 173
LepB inhibitor, 174
Levonadifloxacin, 88
LigBuilder V3 program, 58
Lipononapeptides, 109
Lipopolysaccharide (LPS), 7, 162, 165, 176
Listeria monocytogenes, antibiotic sensitization, 172
LLAMA, 90
LPS transport protein D (LptD), 176
LpxA, 162
LpxC, 162
LpxD, 162, 163
Lugdunin, 164, 165
LuxR, 172
M
MAC-545496, antivirulence activity, 24
Manganese (II), 86
Mechanosensitive ion channel (MscL), 149
Meisenheimer rearrangement, 73, 94
Meropenem, 11, 29, 36
Metabolism Activated Multi-Targeting
(MAMUT), 150
Methionine aminopeptidase, 143
Methylene blue, 38, 39, 42
Methylene blue hybrids, 39, 42
Microbiome, 4, 6, 11, 24, 32, 175, 179, 181
Mips, 169
MOE software, 90
MptbB inhibitors, 170
MRL-494, BamA inhibitor, 176
MRNA, 179
MRSA, introduction, 11
MsbA transporter, inhibitors, 162
Multiple actions, introduction, 21
Multi-targeting, 13, 51, 52, 56, 58, 83, 96,
98, 164
Mupirocin, 62
MUR enzymes, 57
Murepavadin, 176, 177
Mycobacterium tuberculosis, introduction,
2, 3, 14
N
Native mass spectrometry, 167
Near-IR, 126
Nebramine, hybrids, 32
Neomycin, 10
Neomycin, trihybrid, 87
Nitric oxide release, 133, 138
Nitroreductase, 124, 135, 138, 143, 144
Nitroxide derivatives, 134
Nitroxyl, 136
NMR, in-cell technique, 167
Non-transannular interactions, 79
NorA efflux pump, inhibition, 28, 31, 38, 88,
89, 101, 104
O
O-acylation, 67
191
Gold (I), catalyzed cycloaddition, 94
Gold nanoparticles, nanoclusters, 145, 149
Gram stain
Gram-negative, 2, 3
Gram-positive, 2
GSK690693, dual inhibitor, 173
GT-055, hybrid, 33
GT-1, hybrid, 33
Gyrase A, 62
H
Halicin, 12
Helicobacter pylori, 37, 44, 83, 97
HHQ, quinolone signal molecule, 171
High throughput screening, 58
Holliday junctions, 178
Holmes, Sherlock, 87
Host, defence proteins, disarming, 179
HT 61, antibiofilm activity, 164
Humimycins A and B, 165
Hybrids, antibacterial, Chapter 3, 52
Hydrogen peroxide, 41, 129
Hydroxyl radicals, 38
I
Imipenem, 31
INF55, 74
INF55-(Ac)en-MB 2, hybrid, 38
In silico-based design, 31, 57, 60, 89, 90, 96,
180
Iron (III), 12, 85
Irresistin-16, dual action, 61
Isothiazoloquinolone derivative, 60
K
Kanglemycin, 82
Klebsiella pneumonia, introduction, 3, 9, 15
L
LasR protein, 172
LED209, histidine sensor kinase, 173
LepB inhibitor, 174
Levonadifloxacin, 88
LigBuilder V3 program, 58
Lipononapeptides, 109
Lipopolysaccharide (LPS), 7, 162, 165, 176
Listeria monocytogenes, antibiotic sensitization, 172
LLAMA, 90
LPS transport protein D (LptD), 176
LpxA, 162
LpxC, 162
LpxD, 162, 163
Lugdunin, 164, 165
LuxR, 172
M
MAC-545496, antivirulence activity, 24
Manganese (II), 86
Mechanosensitive ion channel (MscL), 149
Meisenheimer rearrangement, 73, 94
Meropenem, 11, 29, 36
Metabolism Activated Multi-Targeting
(MAMUT), 150
Methionine aminopeptidase, 143
Methylene blue, 38, 39, 42
Methylene blue hybrids, 39, 42
Microbiome, 4, 6, 11, 24, 32, 175, 179, 181
Mips, 169
MOE software, 90
MptbB inhibitors, 170
MRL-494, BamA inhibitor, 176
MRNA, 179
MRSA, introduction, 11
MsbA transporter, inhibitors, 162
Multiple actions, introduction, 21
Multi-targeting, 13, 51, 52, 56, 58, 83, 96,
98, 164
Mupirocin, 62
MUR enzymes, 57
Murepavadin, 176, 177
Mycobacterium tuberculosis, introduction,
2, 3, 14
N
Native mass spectrometry, 167
Near-IR, 126
Nebramine, hybrids, 32
Neomycin, 10
Neomycin, trihybrid, 87
Nitric oxide release, 133, 138
Nitroreductase, 124, 135, 138, 143, 144
Nitroxide derivatives, 134
Nitroxyl, 136
NMR, in-cell technique, 167
Non-transannular interactions, 79
NorA efflux pump, inhibition, 28, 31, 38, 88,
89, 101, 104
O
O-acylation, 67